[go: up one dir, main page]

PE20040775A1 - DERIVADOS DE INDOL COMO AGONISTAS DE ADRENORECEPTORES ß2 - Google Patents

DERIVADOS DE INDOL COMO AGONISTAS DE ADRENORECEPTORES ß2

Info

Publication number
PE20040775A1
PE20040775A1 PE2003001024A PE2003001024A PE20040775A1 PE 20040775 A1 PE20040775 A1 PE 20040775A1 PE 2003001024 A PE2003001024 A PE 2003001024A PE 2003001024 A PE2003001024 A PE 2003001024A PE 20040775 A1 PE20040775 A1 PE 20040775A1
Authority
PE
Peru
Prior art keywords
hydroxy
hydroximethyl
indol
carboxamide
propyl
Prior art date
Application number
PE2003001024A
Other languages
English (en)
Inventor
Alan Daniel Brown
Justin Stephen Bryans
Paul Alan Glossop
Rusell Andrew Lewthwaite
Simon John Mantell
Charlotte Alice Louise Lane
Mark Edward Bunnage
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20020292513 external-priority patent/EP1407769A1/en
Priority claimed from EP03290069A external-priority patent/EP1440966A1/en
Application filed by Pfizer filed Critical Pfizer
Publication of PE20040775A1 publication Critical patent/PE20040775A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE LA FORMULA I DONDE n ES 1 a 4; R1 Y R2 SON H o ALQUILO C1-C4; R3 ES H o ALQUILO C1-C6 OPCIONALMENTE SUSTITUIDO CON UN HIDROXI; R4, R5, R6, R7 y R8 SON H, HIDROXI, ALQUILO C1-C6, ALCOXI C1-C6, BENCILOXI, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 5-[(2R)-2-({(2R)-2-HIDROXI-2-[4-HIDROXI-3-(HIDROXIMETIL)FENIL]ETIL}AMINO)PROPIL]-N-(2-METOXIBENCIL)-1H-INDOL-2-CARBOXAMIDA; 5-[(2R)-2-({(2R)-2-HIDROXI-2-[4-HIDROXI-3-(HIDROXIMETIL)FENIL]ETIL}AMINO)PROPIL]-N-(4-(TRIFLUOROMETIL)BENCIL)-1H-INDOL-2-CARBOXAMIDA; N-(2,6-DIMETOXIBENCIL)-5-[(2R)-2-({(2R)-2-HIDROXI-2-[4-HIDROXI-3-(HIDROXIMETIL)FENIL]ETIL}AMINO)PROPIL]-1H-INDOL-2-CARBOXAMIDA; 5-[(2R)-2-({(2R)-2-HIDROXI-2-[4-HIDROXI-3-(HIDROXIMETIL)FENIL]ETIL}AMINO)PROPIL]-N-(3-METOXIBENCIL)-1H-INDOL-2-CARBOXAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION Y UNA COMPOSICION FARMACEUTICA QUE LO CONTIENE. DICHOS COMPUESTOS SON AGONISTAS DE RECEPTORES ADRENERGICOS BETA-2 Y SON UTILES PARA TRATAR ENFERMEDADES, TRASTORNOS Y AFECCIONES INFLAMATORIAS, ALERGICAS O RESPIRATORIAS
PE2003001024A 2002-10-11 2003-10-09 DERIVADOS DE INDOL COMO AGONISTAS DE ADRENORECEPTORES ß2 PE20040775A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20020292513 EP1407769A1 (en) 2002-10-11 2002-10-11 Indole derivatives as beta-2 agonists
EP03290069A EP1440966A1 (en) 2003-01-10 2003-01-10 Indole derivatives useful for the treatment of diseases

Publications (1)

Publication Number Publication Date
PE20040775A1 true PE20040775A1 (es) 2004-12-10

Family

ID=32095049

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003001024A PE20040775A1 (es) 2002-10-11 2003-10-09 DERIVADOS DE INDOL COMO AGONISTAS DE ADRENORECEPTORES ß2

Country Status (25)

Country Link
EP (1) EP1556034B1 (es)
JP (1) JP4490911B2 (es)
KR (1) KR20050047552A (es)
AP (1) AP2005003283A0 (es)
AR (1) AR041566A1 (es)
AT (1) ATE392206T1 (es)
AU (1) AU2003269316A1 (es)
BR (1) BR0315234A (es)
CA (1) CA2499314C (es)
CO (1) CO5550421A2 (es)
DE (1) DE60320439T2 (es)
EA (1) EA200500618A1 (es)
EC (1) ECSP055780A (es)
ES (1) ES2302938T3 (es)
IS (1) IS7751A (es)
MA (1) MA27452A1 (es)
MX (1) MXPA05003866A (es)
NO (1) NO20051406L (es)
OA (1) OA12938A (es)
PA (1) PA8586001A1 (es)
PE (1) PE20040775A1 (es)
PL (1) PL376396A1 (es)
TW (1) TW200424171A (es)
UY (1) UY28013A1 (es)
WO (1) WO2004032921A1 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
EP1460064A1 (en) * 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide derivatives useful as beta-2 agonists
GB0312832D0 (en) * 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
WO2005092841A1 (en) * 2004-03-23 2005-10-06 Pfizer Limited Compounds having beta-agonist activity
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
EP1924553A1 (en) 2005-08-08 2008-05-28 Argenta Discovery Limited Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
JP5006330B2 (ja) 2005-10-21 2012-08-22 ノバルティス アーゲー Ｉｌ１３に対するヒト抗体および治療的使用
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
NZ570693A (en) 2006-03-20 2011-02-25 Pfizer Ltd Amine derivatives
KR20080110925A (ko) 2006-04-21 2008-12-19 노파르티스 아게 아데노신 ａ２ａ 수용체 효능제로서 사용하기 위한 퓨린 유도체
BRPI0714463A2 (pt) 2006-07-19 2013-04-02 Astrazeneca Ab compostos de espiropiperidina tricÍclicos, sua sÍntese e seus usos como moduladores de atividade receptora de quimiocina
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
JP4604129B2 (ja) 2006-12-19 2010-12-22 アストラゼネカ・アクチエボラーグ ムスカリン受容体アンタゴニストとしてのキヌクリジノール誘導体
NZ577939A (en) 2007-01-10 2011-03-31 Irm Llc Compounds and compositions as channel activating protease inhibitors
EA200901082A1 (ru) 2007-02-09 2010-02-26 Айрм Ллк Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы
EP2332933A1 (en) 2007-05-07 2011-06-15 Novartis AG Epithelial sodium channel (ENaC) inhibitors
NZ585789A (en) 2007-12-10 2012-03-30 Novartis Ag Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
EA017627B1 (ru) 2008-05-13 2013-01-30 Астразенека Аб Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора
AU2009252938B2 (en) 2008-05-27 2012-04-26 Astrazeneca Ab Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states
EA201001848A1 (ru) 2008-06-10 2011-08-30 Новартис Аг Производные пиразина в качестве блокаторов эпителиальных натриевых каналов
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
WO2010067102A1 (en) 2008-12-09 2010-06-17 Astrazeneca Ab Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
PT2379507E (pt) 2008-12-30 2014-01-21 Pulmagen Therapeutics Inflammation Ltd Compostos de sulfonamida para o tratamento de desordens respiratórias
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
JP2013508414A (ja) 2009-10-22 2013-03-07 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症および他の慢性疾患の治療のための組成物
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
US9102671B2 (en) 2011-02-25 2015-08-11 Novartis Ag Compounds and compositions as TRK inhibitors
AR085509A1 (es) 2011-03-09 2013-10-09 Bayer Cropscience Ag Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas
PE20141614A1 (es) 2011-06-10 2014-11-20 Chiesi Farma Spa Compuestos con actividad antagonista de los receptores muscarinicos y actividad agonista del receptor beta2 adrenergico
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
EP2755652B1 (en) 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
BR112015012746A2 (pt) 2012-12-06 2017-07-11 Chiesi Farm Spa compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos
PE20151216A1 (es) 2012-12-06 2015-09-08 Chiesi Farma Spa Compuestos con actividad antagonista de los receptores muscarinicos y actividad agonista del receptor beta2 adrenergico
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
AR099336A1 (es) 2014-02-17 2016-07-13 Bayer Cropscience Ag Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas
MX2016013981A (es) 2014-04-24 2016-11-15 Novartis Ag Derivados de amino-piridina como inhibidores de fosfatidil-inositol-3-cinasa.
KR20160141856A (ko) 2014-04-24 2016-12-09 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체
KR20160141855A (ko) 2014-04-24 2016-12-09 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피라진 유도체
WO2020250116A1 (en) 2019-06-10 2020-12-17 Novartis Ag Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
EP4021572A1 (en) 2019-08-28 2022-07-06 Novartis AG Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
AU2021296221A1 (en) 2020-06-26 2023-02-02 Mylan Pharma Uk Limited Formulations including 5-(3-(3-hydroxyphenoxy)azetidin-1-yl)-5-methyl-2,2-diphenylhexanamide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU675536B2 (en) * 1993-06-14 1997-02-06 Pfizer Inc. Secondary amines as antidiabetic and antiobesity agents
EP0801060A1 (en) * 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
EP0822185A1 (en) * 1996-07-31 1998-02-04 Pfizer Inc. B-3-adrenergic agonists as antidiabetic and antiobesity agents

Also Published As

Publication number Publication date
DE60320439D1 (de) 2008-05-29
NO20051406L (no) 2005-04-22
AR041566A1 (es) 2005-05-18
JP4490911B2 (ja) 2010-06-30
JP2006511596A (ja) 2006-04-06
BR0315234A (pt) 2005-08-23
MA27452A1 (fr) 2005-07-01
AP2005003283A0 (en) 2005-06-30
DE60320439T2 (de) 2009-05-20
CA2499314A1 (en) 2004-04-22
AU2003269316A1 (en) 2004-05-04
ATE392206T1 (de) 2008-05-15
EP1556034A1 (en) 2005-07-27
TW200424171A (en) 2004-11-16
ECSP055780A (es) 2005-08-11
OA12938A (en) 2006-10-13
CA2499314C (en) 2010-08-24
KR20050047552A (ko) 2005-05-20
UY28013A1 (es) 2004-04-30
CO5550421A2 (es) 2005-08-31
PL376396A1 (en) 2005-12-27
EA200500618A1 (ru) 2005-12-29
EP1556034B1 (en) 2008-04-16
ES2302938T3 (es) 2008-08-01
PA8586001A1 (es) 2005-02-04
MXPA05003866A (es) 2005-06-22
WO2004032921A1 (en) 2004-04-22
IS7751A (is) 2005-03-17

Similar Documents

Publication Publication Date Title
PE20040775A1 (es) DERIVADOS DE INDOL COMO AGONISTAS DE ADRENORECEPTORES ß2
RU2498988C2 (ru) Ингибиторы активности протеинтирозинкиназы
PE20050420A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
PE20090423A1 (es) Compuestos moduladores de sirtuina
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
CR7496A (es) Piridinoilpiperidinas como agonistas de 5- ht1f
CY1108908T1 (el) Ενωσεις κινολινονης - καρβοξαμιδης ως αγωνιστες υποδοχεων 5-ητ4
RU2502730C2 (ru) Сульфонамидные соединения и их применение
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20060693A1 (es) Nuevos derivados de trifluorometansulfonanilida oxamida eter
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
DOP2004000888A (es) 2-hidroxi-3-diaminoalcanos de benzamida (benzamide 2-hydroxy-3-diaminoalkanes
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
RU2433997C2 (ru) Ингибиторы цитозольной фосфолипазы a2
EA201070535A1 (ru) Новые агонисты глюкокортикоидных рецепторов
PE20061290A1 (es) Derivados de 1-benzil-indol-2-carboxamida
ATE384058T1 (de) Thiazolderivate
ECSP099411A (es) Derivados de aril sulfamida y métodos para su uso
PE20061163A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos
PE20051136A1 (es) Derivados de sulfonamida
RU2012120759A (ru) Новые композиции для предупреждения и/или лечения дегенеративных расстройств центральной нервной системы
PE20030718A1 (es) Lactamas como antagonistas de taquiquininas
RU2394031C2 (ru) Соли четвертичного аммония в качестве антагонистов м3
BRPI0417858A (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
AR053561A1 (es) Compuestos novedosos, isomeros de los mismos o las sales farmaceuticamente aceptables de los mismos como el antagonista del receptor vaniloide y las composiciones farmaceuticas que contienen los mismos

Legal Events

Date Code Title Description
FC Refusal